Arya M, Kalsi J, Kelly J, Muneer A. Malignant and premalignant lesions of the penis. BMJ (Clin Res ed). 2013;346:f1149.
Moses KA, Winer A, Sfakianos JP, Poon SA, Kent M, Bernstein M, et al. Contemporary management of penile cancer: greater than 15 year MSKCC experience. Can J Urol. 2014;21:7201–6.
Ornellas AA, Kinchin EW, Nóbrega BLB, Wisnescky A, Koifman N, Quirino R. Surgical treatment of invasive squamous cell carcinoma of the penis: Brazilian National Cancer Institute long-term experience. J Surg Oncol. 2008;97:487–95.
Rautava J, Syrjanen S. Biology of human papillomavirus infections in head and neck carcinogenesis. Head Neck Pathol. 2012;6 Suppl 1:S3–15.
Munoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol. 2000;19(1–2):1–5.
Heideman DM, Bleeker MG, Ahmed H, Arya M, Horenblas S, Snijders PF, et al. Molecular biology of penile cancer. In: Muneer A, Arya M, Horenblas S, editors. Textbook of penile cancer. London: Springer; 2012. p. 13–25.
Stewart CL, Soria AM, Hamel PA. Integration of the pRB and p53 cell cycle control pathways. J Neurooncol. 2001;51(3):183–204.
Poetsch M, Schuart B-J, Schwesinger G, Kleist B, Protzel C. Screening of microsatellite markers in penile cancer reveals differences between metastatic and nonmetastatic carcinomas. Modern Path: Off J US Can Acad Pathol Inc. 2007;20:1069–77.
Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, et al. 5[prime] CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1995;1(7):686–92.
Razin A, Cedar H. DNA methylation and gene expression. Microbiol Rev. 1991;55(3):451–8.
Poetsch M, Hemmerich M, Kakies C, Kleist B, Wolf E, vom Dorp F, et al. Alterations in the tumor suppressor gene p16(INK4A) are associated with aggressive behavior of penile carcinomas. Virchows Arch. 2011;458(2):221–9.
Zhu Y, Zhou XY, Yao XD, Dai B, Ye DW. The prognostic significance of p53, Ki-67, epithelial cadherin and matrix metalloproteinase-9 in penile squamous cell carcinoma treated with surgery. BJU Int. 2007;100:204–8.
Gunia S, Kakies C, Erbersdobler A, Hakenberg OW, Koch S, May M. Expression of p53, p21 and cyclin D1 in penile cancer: p53 predicts poor prognosis. J Clin Pathol. 2012;65(3):232–6.
Martins ACP, Faria SM, Cologna AJ, Suaid HJ, Tucci S. Immunoexpression of p53 protein and proliferating cell nuclear antigen in penile carcinoma. J Urol. 2002;167:89–92; discussion 3.
Cubilla AL, Lloveras B, Alejo M, Clavero O, Chaux A, Kasamatsu E, et al. Value of p16(INK)4(a) in the pathology of invasive penile squamous cell carcinomas: a report of 202 cases. Am J Surg Pathol. 2011;35:253–61.
Lopes A, Bezerra ALR, Pinto CAL, Serrano SV, de MellO CA, Villa LL. p53 as a new prognostic factor for lymph node metastasis in penile carcinoma: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. J Urol. 2002;168:81–6.
Gunia S, Erbersdobler A, Hakenberg OW, Koch S, May M. p16(INK4a) is a marker of good prognosis for primary invasive penile squamous cell carcinoma: a multi-institutional study. J Urol. 2012;187(3):899–907.
Licitra L, Perrone F, Bossi P, Suardi S, Mariani L, Artusi R, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2006;24:5630–6.
Kayes OJ, Loddo M, Patel N, Patel P, Minhas S, Ambler G, et al. DNA replication licensing factors and aneuploidy are linked to tumor cell cycle state and clinical outcome in penile carcinoma. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009;15:7335–44.
May M, Burger M, Otto W, Hakenberg OW, Wieland WF, May D, et al. Ki-67, mini-chromosome maintenance 2 protein (MCM2) and geminin have no independent prognostic relevance for cancer-specific survival in surgically treated squamous cell carcinoma of the penis. BJU Int. 2013;112:E383–90.
Guimarães GC, Leal MLO, Campos RSM, Zequi SDC, da Fonseca FP, da Cunha IW, et al. Do proliferating cell nuclear antigen and MIB-1/Ki-67 have prognostic value in penile squamous cell carcinoma? Urology. 2007;70:137–42.
Andersson P, Kolaric A, Windahl T, Kirrander P, Söderkvist P, Karlsson MG. PIK3CA, HRAS and KRAS gene mutations in human penile cancer. J Urol. 2008;179:2030–4.
Gou HF, Li X, Qiu M, Cheng K, Li LH, Dong H, et al. Epidermal growth factor receptor (EGFR)-RAS signaling pathway in penile squamous cell carcinoma. PLoS One. 2013;8(4):e62175.
Protzel C, Kakies C, Kleist B, Poetsch M, Giebel J. Down-regulation of the metastasis suppressor protein KAI1/CD82 correlates with occurrence of metastasis, prognosis and presence of HPV DNA in human penile squamous cell carcinoma. Virchows Arch. 2008;452(4):369–75.
Joory KD, Levick JR, Mortimer PS, Bates DO. Vascular endothelial growth factor-C (VEGF-C) expression in normal human tissues. Lymphat Res Biol. 2006;4(2):73–82.
De Paula AAP, Motta ED, Alencar RDC, Saddi VA, da Silva RC, Caixeta GN, et al. The impact of cyclooxygenase-2 and vascular endothelial growth factor C immunoexpression on the prognosis of penile carcinoma. J Urol. 2012;187(1):134–40.
Minardi D, d’Anzeo G, Lucarini G, Filosa A, Zizzi A, Simonetti O, et al. D2-40 immunoreactivity in penile squamous cell carcinoma: a marker of aggressiveness. Hum Pathol. 2011;42:1596–602.
Price JT, Thompson EW. Mechanisms of tumour invasion and metastasis: emerging targets for therapy. Expert Opin Ther Targets. 2002;6:217–33.
Campos RSM, Lopes A, Guimarães GC, Carvalho AL, Soares FA. E-cadherin, MMP-2, and MMP-9 as prognostic markers in penile cancer: analysis of 125 patients. Urology. 2006;67:797–802.
Kudo Y, Siriwardena BS, Hatano H, Ogawa I, Takata T. Periostin: novel diagnostic and therapeutic target for cancer. Histol Histopathol. 2007;22(10):1167–74.
Gunia S, Jain A, Koch S, Denzinger S, Götz S, Niessl N, et al. Periostin expression correlates with pT-stage, grading and tumour size, and independently predicts cancer-specific survival in surgically treated penile squamous cell carcinomas. J Clin Pathol. 2013;66:297–301.
Han Z-D, He H-C, Bi X-C, Qin W-J, Dai Q-S, Zou J, et al. Expression and clinical significance of CD147 in genitourinary carcinomas. J Surg Res. 2010;160:260–7.
Soares FA, da Cunha IW, Guimaraes GC, Nonogaki S, Campos RS, Lopes A. The expression of metaloproteinases-2 and -9 is different according to the patterns of growth and invasion in squamous cell carcinoma of the penis. Virchows Arch. 2006;449(6):637–46.
Ghittoni R, Accardi R, Hasan U, Gheit T, Sylla B, Tommasino M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes. 2010;40(1):1–13.
Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 2004;78(21):11451–60.
Miralles-Guri C, Bruni L, Cubilla AL, Castellsague X, Bosch FX, de Sanjose S. Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol. 2009;62(10):870–8.
Moreno V, Bosch FX, Muñoz N, Meijer CJLM, Shah KV, Walboomers JMM, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet. 2002;359(9312):1085–92.
Feber A, Arya M, de Winter P, Saqib M, Nigam R, Malone PR, et al. Epigenetics markers of metastasis and HPV-induced tumorigenesis in penile cancer. Clin Cancer Res. 2015;21(5):1196–206.
Kuasne H, Colus IM, Busso AF, Hernandez-Vargas H, Barros-Filho MC, Marchi FA, et al. Genome-wide methylation and transcriptome analysis in penile carcinoma: uncovering new molecular markers. Clin Epigenet. 2015;7(1):46.
Ferreux E, Lont AP, Horenblas S, Gallee MP, Raaphorst FM, von Knebel Doeberitz M, et al. Evidence for at least three alternative mechanisms targeting the p16INK4A/cyclin D/Rb pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus. J Pathol. 2003;201(1):109–18.
Busso-Lopes AF, Marchi FA, Kuasne H, Scapulatempo-Neto C, Trindade-Filho JC, de Jesus CM, et al. Genomic profiling of human penile carcinoma predicts worse prognosis and survival. Cancer Prev Res (Phila). 2015;8(2):149–56.
Dang CV. MYC on the path to cancer. Cell. 2012;149(1):22–35.
Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002;2(6):420–30.
Kato H, Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer. 1977;40:1621–8.
Touloupidis S, Zisimopoulos A, Giannakopoulos S, Papatsoris AG, Kalaitzis C, Thanos A. Clinical usage of the squamous cell carcinoma antigen in patients with penile cancer. Int J Urol: Off J Japn Urol Assoc. 2007;14:174–6.
Minardi D, Lucarini G, Filosa A, Zizzi A, Simonetti O, Offidani AM, et al. Prognostic value of CD44 expression in penile squamous cell carcinoma: a pilot study. Cellular Oncol (Dordrecht). 2012;35:377–84.
Balermpas P, Rödel F, Rödel C, Krause M, Linge A, Lohaus F, et al. CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: a multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). Int J Cancer. 2016;138(1):171–81.
Lohneis P, Boral S, Kaufmann AM, Lehmann A, Schewe C, Dietel M, et al. Human papilloma virus status of penile squamous cell carcinoma is associated with differences in tumour-infiltrating T lymphocytes. Virchows Arch. 2015;466(3):323–31.